EXELIXIS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EXELIXIS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 29, 2017 | $120.07M | Feb 26, 2018 |
| FY2017 | Sep 29, 2017 | $152.51M | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $99.01M | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $80.89M | Feb 26, 2018 |
| FY2016 | Dec 31, 2016 | $77.58M | Feb 27, 2017 |
| FY2017 | Dec 30, 2016 | $77.58M | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $62.19M | Feb 26, 2018 |
| FY2017 | Jul 1, 2016 | $36.25M | Feb 26, 2018 |
| FY2016 | Jun 30, 2016 | $36.25M | Feb 27, 2017 |
| FY2017 | Apr 1, 2016 | $15.43M | Feb 26, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.32B | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $2.17B | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $1.83B | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $1.61B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.43B | Feb 6, 2024 |
| FY2020 | Jan 1, 2021 | $270.05M | Feb 11, 2021 |
| FY2020 | Oct 2, 2020 | $231.09M | Feb 11, 2021 |
| FY2020 | Jul 3, 2020 | $259.48M | Feb 11, 2021 |
| FY2020 | Apr 3, 2020 | $226.92M | Feb 11, 2021 |
| FY2020 | Jan 3, 2020 | $240.31M | Feb 11, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $7.35M | Mar 2, 2015 |
| FY2014 | Sep 30, 2014 | $6.29M | Mar 2, 2015 |
| FY2014 | Jun 30, 2014 | $6.56M | Mar 2, 2015 |
| FY2014 | Mar 31, 2014 | $4.91M | Mar 2, 2015 |
| FY2014 | Dec 31, 2013 | $4.35M | Mar 2, 2015 |
| FY2014 | Sep 30, 2013 | $5.47M | Mar 2, 2015 |
| FY2014 | Jun 30, 2013 | $11.86M | Mar 2, 2015 |
| FY2014 | Mar 31, 2013 | $9.67M | Mar 2, 2015 |
| FY2013 | Dec 31, 2012 | $7.81M | Feb 20, 2014 |
| FY2013 | Sep 30, 2012 | $13.31M | Feb 20, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jan 1, 2021 | $191.32M | Feb 11, 2021 |
| FY2020 | Oct 2, 2020 | $159.86M | Feb 11, 2021 |
| FY2020 | Jul 3, 2020 | $169.51M | Feb 11, 2021 |
| FY2020 | Apr 3, 2020 | $184.59M | Feb 11, 2021 |
| FY2020 | Jan 3, 2020 | $184.41M | Feb 11, 2021 |
| FY2020 | Sep 27, 2019 | $184.23M | Feb 11, 2021 |
| FY2020 | Jun 28, 2019 | $186.14M | Feb 11, 2021 |
| FY2020 | Mar 29, 2019 | $172.08M | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | $168.87M | Feb 25, 2020 |
| FY2019 | Sep 29, 2018 | $155.59M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $782.57M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $521.27M | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $207.77M | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $182.28M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $231.06M | Feb 6, 2024 |
| FY2020 | Jan 1, 2021 | $28.39M | Feb 11, 2021 |
| FY2020 | Oct 2, 2020 | ($32.04M) | Feb 11, 2021 |
| FY2020 | Jul 3, 2020 | $66.82M | Feb 11, 2021 |
| FY2020 | Apr 3, 2020 | $48.61M | Feb 11, 2021 |
| FY2020 | Jan 3, 2020 | $68.74M | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $872.19M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $604.62M | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $170.89M | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $201.48M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $286.67M | Feb 6, 2024 |
| FY2020 | Jan 1, 2021 | $24.30M | Feb 11, 2021 |
| FY2020 | Oct 2, 2020 | ($42.58M) | Feb 11, 2021 |
| FY2020 | Jul 3, 2020 | $75.53M | Feb 11, 2021 |
| FY2020 | Apr 3, 2020 | $52.81M | Feb 11, 2021 |
| FY2020 | Jan 3, 2020 | $77.32M | Feb 11, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $825.00M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $910.41M | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $1.04B | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $891.81M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $693.72M | Feb 6, 2024 |
| FY2022 | Jan 1, 2021 | $547.85M | Feb 7, 2023 |
| FY2021 | Jan 3, 2020 | $336.96M | Feb 18, 2022 |
| FY2020 | Dec 28, 2018 | $182.26M | Feb 11, 2021 |
| FY2019 | Dec 29, 2017 | $112.17M | Feb 25, 2020 |
| FY2016 | Dec 31, 2016 | $95.97M | Feb 27, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $518.73M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $492.13M | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $542.71M | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $459.86M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $401.72M | Feb 6, 2024 |
| FY2022 | Jan 1, 2021 | $293.36M | Feb 7, 2023 |
| FY2021 | Jan 3, 2020 | $228.24M | Feb 18, 2022 |
| FY2020 | Dec 28, 2018 | $206.37M | Feb 11, 2021 |
| FY2019 | Dec 29, 2017 | $159.33M | Feb 25, 2020 |
| FY2016 | Dec 31, 2016 | $116.15M | Feb 27, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $884.27M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $699.97M | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $333.32M | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $362.61M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $400.80M | Feb 6, 2024 |
| FY2022 | Jan 1, 2021 | $208.98M | Feb 7, 2023 |
| FY2021 | Jan 3, 2020 | $526.96M | Feb 18, 2022 |
| FY2020 | Dec 28, 2018 | $415.72M | Feb 11, 2021 |
| FY2019 | Dec 29, 2017 | $165.61M | Feb 25, 2020 |
| FY2016 | Dec 31, 2016 | $206.30M | Feb 27, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $8.43M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $28.44M | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $40.47M | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | $27.71M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $54.23M | Feb 6, 2024 |
| FY2022 | Jan 1, 2021 | $30.35M | Feb 7, 2023 |
| FY2021 | Jan 3, 2020 | $12.83M | Feb 18, 2022 |
| FY2020 | Dec 28, 2018 | $33.30M | Feb 11, 2021 |
| FY2019 | Dec 29, 2017 | $21.14M | Feb 25, 2020 |
| FY2016 | Dec 31, 2016 | $1.70M | Feb 27, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.84B | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $2.95B | Feb 10, 2026 |
| FY2024 | Dec 29, 2023 | $2.94B | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $3.07B | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $2.62B | Feb 7, 2023 |
| FY2021 | Jan 1, 2021 | $2.14B | Feb 18, 2022 |
| FY2020 | Jan 3, 2020 | $1.89B | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | $1.42B | Feb 25, 2020 |
| FY2018 | Dec 29, 2017 | $655.29M | Feb 22, 2019 |
| FY2016 | Dec 31, 2016 | $597.54M | Feb 27, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $683.10M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $703.49M | Feb 10, 2026 |
| FY2024 | Dec 29, 2023 | $678.45M | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $583.06M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $405.62M | Feb 7, 2023 |
| FY2021 | Jan 1, 2021 | $258.22M | Feb 18, 2022 |
| FY2020 | Jan 3, 2020 | $199.70M | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | $134.83M | Feb 25, 2020 |
| FY2018 | Dec 29, 2017 | $370.33M | Feb 22, 2019 |
| FY2016 | Dec 31, 2016 | $508.22M | Feb 27, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.16B | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $2.24B | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | $2.26B | Feb 10, 2026 |
| FY2025 | Dec 30, 2022 | $2.49B | Feb 10, 2026 |
| FY2024 | Dec 31, 2021 | $2.21B | Feb 11, 2025 |
| FY2023 | Jan 1, 2021 | $1.88B | Feb 6, 2024 |
| FY2022 | Jan 3, 2020 | $1.69B | Feb 7, 2023 |
| FY2021 | Dec 28, 2018 | $1.29B | Feb 18, 2022 |
| FY2020 | Dec 31, 2017 | $284.96M | Feb 11, 2021 |
| FY2019 | Dec 29, 2017 | $284.96M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $63.68M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $63.68M | Feb 10, 2026 |
| FY2024 | Dec 29, 2023 | $63.68M | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $63.68M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $63.68M | Feb 7, 2023 |
| FY2021 | Jan 1, 2021 | $63.68M | Feb 18, 2022 |
| FY2020 | Jan 3, 2020 | $63.68M | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | $63.68M | Feb 25, 2020 |
| FY2018 | Dec 29, 2017 | $63.68M | Feb 22, 2019 |
| FY2016 | Dec 31, 2016 | $63.68M | Feb 27, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | ($76.83M) | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | ($98.65M) | Feb 10, 2026 |
| FY2024 | Dec 29, 2023 | ($173.35M) | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | ($34.23M) | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | ($216.51M) | Feb 7, 2023 |
| FY2021 | Jan 1, 2021 | ($447.57M) | Feb 18, 2022 |
| FY2020 | Jan 3, 2020 | ($559.35M) | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | ($880.36M) | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | ($1.57B) | Feb 22, 2019 |
| FY2018 | Dec 29, 2017 | ($1.83B) | Feb 22, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $482.49M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | $217.37M | Feb 10, 2026 |
| FY2024 | Dec 29, 2023 | $262.99M | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $501.20M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $647.17M | Feb 7, 2023 |
| FY2021 | Jan 1, 2021 | $319.22M | Feb 18, 2022 |
| FY2020 | Jan 3, 2020 | $266.50M | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | $314.78M | Feb 25, 2020 |
| FY2019 | Dec 29, 2017 | $183.16M | Feb 25, 2020 |
| FY2016 | Dec 31, 2016 | $151.69M | Feb 27, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 29, 2017 | $0 | Feb 26, 2018 |
| FY2016 | Dec 31, 2016 | $189.12M | Feb 27, 2017 |
| FY2017 | Dec 30, 2016 | $189.12M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $417.94M | Feb 27, 2017 |
| FY2015 | Dec 31, 2014 | $356.97M | Feb 29, 2016 |
| FY2014 | Dec 31, 2013 | $347.24M | Mar 2, 2015 |
| FY2013 | Dec 31, 2012 | $335.74M | Feb 20, 2014 |
| FY2012 | Dec 31, 2011 | $181.52M | Feb 21, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 2 | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | 1 | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | 0 | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | 0 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 6, 2024 |
| FY2020 | Jan 1, 2021 | 0 | Feb 11, 2021 |
| FY2020 | Oct 2, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Jul 3, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Apr 3, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Jan 3, 2020 | 0 | Feb 11, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 2 | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | 1 | Feb 10, 2026 |
| FY2025 | Dec 29, 2023 | 0 | Feb 10, 2026 |
| FY2024 | Dec 30, 2022 | 0 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 6, 2024 |
| FY2020 | Jan 1, 2021 | 0 | Feb 11, 2021 |
| FY2020 | Oct 2, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Jul 3, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Apr 3, 2020 | 0 | Feb 11, 2021 |
| FY2020 | Jan 3, 2020 | 0 | Feb 11, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 262.48M | Feb 10, 2026 |
| FY2025 | Jan 3, 2025 | 281.73M | Feb 10, 2026 |
| FY2024 | Dec 29, 2023 | 302.79M | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | 323.95M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 318.84M | Feb 7, 2023 |
| FY2021 | Jan 1, 2021 | 311.63M | Feb 18, 2022 |
| FY2020 | Jan 3, 2020 | 304.83M | Feb 11, 2021 |
| FY2019 | Dec 28, 2018 | 299.88M | Feb 25, 2020 |
| FY2018 | Dec 29, 2017 | 296.21M | Feb 22, 2019 |
| FY2016 | Dec 31, 2016 | 289.92M | Feb 27, 2017 |